Even though HER2-targeted therapies for advanced GC have not been very successful, recent trials with trastuzumab deruxtecan have led to significant improvements in response and overall survival (OS), as compared with standard therapies, among pretreated patients with HER2+ GC [6]. The gene discussed is ERBB2; the disease is gastric cancer.